Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLAY pneumococcal revaccination study
2008-006194-33Phase 3Completed
- Sponsor
- Wyeth
- Start
- Feb 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Prevnar 13 in invasive pneumococcal disease (IPD) and pneumococcal disease (2 arms), sponsored by Wyeth. Primary endpoints: Serotype-specific IgG response by ELISA and Serotype-specific functional antibody response by OPA. Started Feb 2009; status: completed.
02
Drugs
Prevnar 13
03
Conditions
invasive pneumococcal disease (IPD)pneumococcal disease
Beyond the preview
Go deeper on 2008-006194-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006194-33.